The management of HIV-hodgkin lymphoma

Abstract

Since 1996, the availability of combination antiretroviral therapy (cART) has led to improvements in immune status among HIV-infected persons, reducing AIDS-related morbidity and prolonging survival. However, despite the impact of cART on HIV-related mortality, malignancies remain an important cause of death in the current era. The use of cART was also associated with reduced incidence of the two major AIDS-associated malignancies - Kaposi's sarcoma (KS) and high-grade non-Hodgkin lymphoma (NHL). However, among non-AIDS-defining cancers, an increased risk of Hodgkin lymphoma (HL), anal cancer, lung cancer, and liver cancer has been observed.